| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_50abd376b9f08233b86bc85e1f810bcc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e230db766e940ca9854b511da42c017f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e9124e0cc500bc25c454e1f449a38c09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e987bcbaba75e04ceec088aee5d0d24d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7db222f5f1ba0eb7e3f1a67a21bba5a4 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4166
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4168
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate |
2008-09-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d8b86b365877abad60b94f86e575b893
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a36d575aab56bf9f1136e4102f4b5cfa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef66fd72060b19cbf1ba35ab6e568a3d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d926b992be16fdefeabf5ede26ee47fc |
| publicationDate |
2009-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2009048698-A9 |
| titleOfInvention |
Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents |
| abstract |
The present invention provides for methods of using terf-butyl alcohol (TBA) co-solvent systems in the formulation and production of a pharmaceutical agent with low solubility. The present invention also provides for pharmaceutical compositions made using the novel co-solvent system. In one embodiment, the invention provides for a method of making dantrolene sodium (DS) formulation for intravenous use (DS-IV). This instantaneous reconstitution of the DS-IV product constitutes a significant improvement in the pharmacotherapy of patients undergoing malignant hyperthermia during surgery. |
| priorityDate |
2007-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |